Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery

Hamdy Awad¹
Ahmed Ahmed²
Richard D Urman³
Nicoleta Stoica³,⁴
Sergio D Bergese¹,⁵

¹Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA;
²Department of Anesthesiology, University of Texas, Houston, TX, USA;
³Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;
⁴Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH, USA;
⁵Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Abstract: In 2001, a group of European academic surgeons created the Enhanced Recovery After Surgery (ERAS) study group and established the first official ERAS protocol. One of the most significant challenges during ERAS implementation is variability of drugs used throughout the perioperative period. Pharmacogenomic testing (blood or saliva) results (obtained within approximately 48 hrs) provide guidelines on how to prescribe the optimal drug with the optimal dosage to each patient based on an individual’s unique genetic profile. Pharmacogenomic testing of various methods of multimodal analgesia is an essential element of ERAS protocols spanning the entire perioperative period to ultimately optimize postoperative pain control. The key goal for anesthetic management in ERAS protocols is to facilitate rapid emergence by using the shortest acting agents available, thus accelerating recovery and reducing length of stay, hospital expenses, and postoperative complications. Postoperative nausea and vomiting (PONV) is an additional challenge that should be overcome to ensure an enhanced recovery and shorter length of stay with the use of antiemetics. Postoperative ileus (POI) can result in longer hospital stay with increasing susceptibility to associated morbidities along with an increase in associated hospitalization costs. Genetics-guided pharmacotherapy and its impact on clinical outcomes should be thoroughly studied for better understanding and managing drug administration in the settings of ERAS.

Keywords: pharmacogenomics, perioperative outcome, pharmacogenomics testing, Enhanced Recovery After Surgery

Introduction
Enhanced Recovery After Surgery (ERAS) is a multidisciplinary perioperative approach that has been developed and adopted over the last twenty years to provide a perioperative value-based care and improvement of the surgical outcomes.¹ The significance of ERAS practices stems from both its improvement of the clinical outcome and from its recognizable economic potential. In addition to the ability to offer better perioperative care and a reduced length of hospital stay, ERAS implementation has shown a valuable cost reduction associated with perioperative hospitalization.²,³ Nonetheless, ERAS implementation has challenges that should be addressed. One of the most significant challenges during ERAS implementation is variability of drugs used throughout the perioperative period.⁴

Current evidence suggests that patients may exhibit variable responses to standard drugs and doses used, which would render uniform drug administration less than ideal, instead requiring individual adaptation.⁵,⁶ Guidance for drug
These genetic differences are responsible for each individual’s susceptibility to diseases and unique drug response. Drugs rely on enzymes to reach their target, have therapeutic effects, and then are cleared from the body. Due to the high variability of the genes coding these enzymes, patients may have overactive, normal, or underactive enzymes. Therefore, a given drug and a given dose are not going to have the same effect in each individual. Given these variations, drug administration in ERAS protocol should ideally be individualized.

Pharmacogenomic testing has been designed particularly to improve drug administration. The results of these tests provide guidelines on how to prescribe the optimal drug with the optimal dosage to each patient based on individual’s unique genetic profile. An important consideration of pharmacogenomics testing is the cost effectiveness in treatment. According to a review done by Verbelen et al, in over 68 distinct drugs used in a multitude of clinical specialties, more than half of all studies which reached a conclusion for their analyzed drug reported pharmacogenomics impacted treatment to be either cost dominant or cost-effective. Two genetic variations of interest concerning drug-response variability are SNPs (single-nucleotide polymorphisms) and CNVs (copy-number variations) occurring inside the human genome. Due to the time-consuming and resource-demanding nature of mapping an entire genome, modern day pharmacogenomic testing often utilizes “per gene” testing for patient-specific results identifying at-risk predispositions for certain drugs. TPMT (thiopurine methyltransferase) and CYP2D6 gene tests are among the most commonly utilized today due to their cost-effectiveness and rapid results. Preemptive testing of several high-risk pharmacogenes is another strategy recently used to obtain patient-specific results before utilizing at-risk drugs with a reputation for patient variability. Our objective is to review the most recent elements of ERAS practices that involve drug administration and the feasibility of introducing pharmacogenomics testing in ERAS practices to guide drug administration.

Anxiolytics

Preoperative stress and anxiety negatively affect perioperative outcomes. Establishing a clear strategy to control preoperative anxiety is essential for rapid recovery and early discharge. Anxiolytics could be achieved via various approaches either pharmacologically or non-pharmacologically. Non-pharmacological approaches rely mainly on providing preoperative patient counseling and education about the surgery and the perioperative plan and management of patient expectations to help reduce anxiety. Although these approaches have the advantage of avoiding premedication-related adverse effects, they require continuous skillful communication and a buildup of patient rapport to successfully relieve anxiety.

On the other hand, the pharmacological approach carries the drawbacks of drug-related adverse effects, inappropriateness of the premedication drugs for some patients due to comorbidities, and the possibility of suboptimum therapeutic effects. From an ERAS standpoint, it is recommended to avoid long-acting anxiolytics 12 hrs before surgery as it may interfere with early mobilization and return of gut function and early feeding with longer hospital stay. Therefore, anxiolytics are advised to be restricted to the short-acting drugs that would assist in performing regional anesthetic procedures.

Benzodiazepines are the most commonly used anxiolytic premedication drugs. The hepatic CYP enzyme family is responsible for metabolizing most benzodiazepines. Variations and genetic polymorphisms of CYP enzymes have been shown to alter the metabolism and pharmacologic effects of benzodiazepines. For instance, midazolam is metabolized by CYP3A4/5 enzymes. Patients carrying homozygous alleles for CYP3A5*3 have been noticed to have more than 50% induction of these enzymes, and thus a higher rate of metabolizing and eliminating midazolam. However, studies comparing different polymorphisms (CYP3A5*1/*3 and CYP3A5*3/*3) have shown inconsistent variations in midazolam clearance. Despite the extensive midazolam use as anxiolytic premedication before surgical procedures, inconclusive evidence of clinical variations in polymorphisms of CYP3A5 may require further research to show the efficacy of the pharmacogenomics administration of midazolam. Table 1 shows examples of commonly used drugs in anesthesia, metabolizing enzyme, known variants, and their impact on metabolism.

Analgesia

Multimodal analgesia spanning the entire perioperative period is an essential element of ERAS protocols which is used to ultimately lessen postoperative pain. Non-opioid analgesic use is the adopted strategy for perioperative pain control in most ERAS guidelines. Nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and
Patients with the pharmacokinetics. These analgesics provide Additionally, perioperative use of intravenous However, some COX-2 inhibitors carry an Regarding its analgesic The avail- Therefore, it has been recommended to start Concerning multimodal analgesia, it is Alternatively, selective COX-2 inhibitors do not show gastrointestinal side effects and thus reduce the risk of peptic ulceration associated with NSAIDs. However, some COX-2 inhibitors carry an increased cardiovascular risk profile with prolonged use, but this has not been demonstrated with shorter term use. Understanding the pharmacogenomics of NSAIDs may provide the opportunity of appropriately choosing the suitable drug and its optimum dose.

Most of NSAIDs are metabolized by cytochrome P 450 enzymes (CYP450) – namely CYP2C8 and CYP2C9. Genetic polymorphisms of these enzymes play an important role in NSAIDs’ pharmacokinetics. Patients with the wild-type CYP2C8*1 or CYP2C9*1 variant show normal metabolism of the drugs. Poor metabolizers carrying the alleles CYP2C8*2, *3, CYP2C9*2, or *3 experience abnormally high serum levels due to ineffective drug clearance resulting in unexpected toxicity with standard doses. Therefore, it has been recommended to start treatment at half the normal recommended dose in such patients (CYP2C9*2/*3 genotype) to avoid adverse cardiovascular and gastrointestinal events.

### Acetaminophen

Scheduled acetaminophen administration is also recommended by ERAS Society guidelines. Despite its tolerability and minimal side effect profile, overdose is a risk factor for hepatotoxicity. Additionally, the analgesic potential of NSAIDs and selective COX-2 inhibitors is limited by the degree to which other various endogenous neurotransmitter systems (such as the serotonergic, opioid, and cannabinoid) are inhibited. Regarding its analgesic potency, it has been shown that analgesia provided by NSAIDs or opioids combined with acetaminophen is superior to analgesia provided by NSAIDs or opioids only.

### Table 1 Examples of commonly used drugs in anesthesia, corresponding metabolizing enzyme(s), known variants, and their impact on metabolism

<table>
<thead>
<tr>
<th>Drug of interest</th>
<th>Metabolizing enzyme</th>
<th>Variant</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam</td>
<td>CYP3A4/5</td>
<td>CYP3A5*3</td>
<td>50% enzyme induction</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>CYP2C8/9</td>
<td>CYP2C8<em>9</em>1</td>
<td>Normal metabolizer</td>
</tr>
<tr>
<td>Ketamine</td>
<td>Depending on ketamine plasma level:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>– At high levels: CYP3A4</td>
<td>CYP2B6*6/6</td>
<td>Poor metabolizers</td>
</tr>
<tr>
<td></td>
<td>– At clinically relevant levels: CYP2B6</td>
<td>CYP2B6<em>1/1 or CYP2B6</em>1/*1</td>
<td>Low plasma clearance</td>
</tr>
<tr>
<td>Propofol</td>
<td>CYP2B6</td>
<td>CYP2B6*4</td>
<td>Better clearance</td>
</tr>
<tr>
<td>Succinylcholine</td>
<td>BCHE</td>
<td>BCHE<em>FS126, BCHE</em>I3E4-14C and BCHE*328D</td>
<td>Reduced clearance</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>CYP2D6</td>
<td>rs1080985 and rs1694,7</td>
<td>Prolonged effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3892097</td>
<td>Fewer side effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Higher incidence of side effects</td>
</tr>
</tbody>
</table>

Nonsteroidal anti-inflammatory drugs (NSAIDs) NSAIDs inhibit the action of cyclooxygenases (COX-1 and COX-2) on the arachidonic acid which is a cell membrane phospholipid produced during cellular damage. This action prevents prostaglandin production with subsequent decrease of the peripheral nociception and swelling at the time of tissue damage. NSAIDs include nonselective agents, such as aspirin, ibuprofen, ketorolac, and diclofenac, as well as newer selective COX-2 inhibitors such as parecoxib and celecoxib. Currently, NSAIDs at standard doses are verified as part of the multimodal opioid-sparing analgesic approach by all ERAS Society guidelines.

Some of the recognized drawbacks of NSAIDs include their undesirable effects on the cardiovascular and gastrointestinal systems. Alternatively, selective COX-2 inhibitors do not show gastrointestinal side effects and thus provide the opportunity of appropriately choosing the suitable drug and its optimum dose.
Acetaminophen undergoes several processes of extensive hepatic metabolism by multiple enzymes. These enzymes include UDP glucuronosyltransferases (UGT), cytochrome P (CYP), sulfotransferases (SULT), and glutathione-S-transferases (GST). Genetic polymorphisms of these enzymes are a major cause of discrepancies in patients’ responses to acetaminophen administration. Despite the well-established polymorphism in the four enzymes, studies have been limited to UGT genes only. Therefore, studies of genes encoding the other three enzymes are recommended due to their significant contribution in differential drug response.

**N-Methyl D-Aspartate receptor antagonists**

Ketamine is one of the well-known N-Methyl D-Aspartate (NMDA) receptor antagonists. It performs its antagonistic action via noncompetitive inhibition of the excitatory glutamate receptor site on the NMDA channel. Sub-anesthetic, intravenous doses of ketamine administered alongside induction agents have been shown to positively manage postoperative pain and reduce opioid consumption. However, data on ketamine’s analgesic role in elective surgeries are limited. Moreover, side effects such as dizziness and sedation should be considered before its routine use in ERAS guidelines. Therefore, pharmacogenomics testing could play a significant role in providing a comprehensive report on patient’s genetic profiles and responses to ketamine; thus, ketamine dosages could be optimized and adverse events minimized.

Different types of cytochrome enzymes (CYP2B6, CYP2C9, and CYP3A4) are responsible for metabolizing ketamine via N-demethylation into norketamine. Depending on ketamine plasma levels, the primary metabolizing isoenzyme usually changes. For instance, CYP3A4 is the primary metabolizing isoenzyme at higher concentrations of ketamine in plasma, with little contribution from CYP2B6 and CYP2C9. However, at clinically relevant plasma levels, CYP2B6 takes over the responsibility of metabolizing ketamine, with a little assistance from CYP3A4. Because of this, the metabolization of and clearance of ketamine is highly variable and unpredictable, rendering optimum drug dosage a serious challenge. Additionally, individuals with different variants of CYP2B6 alleles have shown significant differences in ketamine metabolism. As such, lower plasma clearance, higher plasma levels, and higher incidence of side effects have been noticed in individuals with CYP2B6*6/*6 genotype than those with CYP2B6*1/*6 or CYP2B6*1/*1 genotype.

**Opioids**

Optimum intraoperative pain control is mandatory for reduction of surgical stress response and enhancement of recovery. Opioid use is a cornerstone for pain control in traditional practices. However, opioid-related side effects are critical barriers for rapid recovery. Therefore, if deemed essential, short-acting (fentanyl and alfentanil) and ultrashort-acting (remifentanil via infusion) opioids have been recommended over morphine by ERAS Guidelines due to their rapid clearance from the system and fewer side effects. Due to the variable rate of opioid metabolism and elimination, dosages should be adjusted to each individual patient so as to minimize the incidence of side effects. A pragmatic study done by UF Health explored the differences in patient responses to opiate medications based on if the individual’s pharmacogenomics profile had been considered or not. They concluded that more extensive research needs to be done on specific medications in order to evaluate the cost-effectiveness and pain control benefits of pharmacogenomics-based opiate treatment. One might argue that testing for opioid metabolism is one example of potentially life-saving pharmacogenomic testing as it can guide short- and long-term therapy and might even prevent an overdose or transition to chronic pain due to inadequate analgesia and opioid use disorder and abuse.

Multiple enzymes are involved in the metabolization of opioids. This provides an opportunity for genetic variability to affect both the efficacy and toxicity of these drugs. Depending on the number of mutant alleles, patients who experience this variability can be classified as ultra-metabolizers with over-functional alleles, extensive-metabolizers with two normal alleles, intermediate-metabolizers with one mutant allele, or poor-metabolizers with two mutant alleles. CYP2D6 enzyme polymorphism is an example of opioid metabolization variability. There are at least 80 identified CYP2D6 alleles. This allows for wide range of enzymatic variability when compared with the wild-type allele. Meaningful differences in clinical responses may also occur due to the variable responses of the mutant alleles on a functional gradient. Therefore, larger studies on this enzyme’s polymorphism are required for a more accurate evaluation and a better correlation to clinical responses.

**Anesthetics**

There are no studies which compare the different anesthetic agents’ used for ERAS to determine evidence-based guidelines. However, the key goal for anesthetic
management in ERAS protocols is to facilitate rapid emergence by using the shortest acting agents available. This has been shown to accelerate recovery and reduce the length of stay, hospital expenses, and postoperative complications.

Depth of anesthesia should be monitored continuously and efficiently to ensure a well-balanced and individualized level of anesthesia to avoid delayed recovery, while still preventing surgical stress and undesired patient awareness. Bispectral index (BIS) monitoring has been used for monitoring the depth of anesthesia, with BIS levels of 40–60 shown to be sufficient and recommended.

Propofol, as one of the commonly used intravenous anesthetic agents, has variable pharmacokinetics attributed to genetic variation of the drug metabolizing enzymes. It undergoes metabolism by hepatic CYP2B6 enzyme and O-glucuronidation by UGT1A9. Polymorphisms of the genes coding for these enzymes affect elimination and clearance of propofol from the system resulting in discrepancies in the serum drug levels. For instance, patients with CYP2B6*4 alleles have been shown to have reduced drug clearance which increases their susceptibility to drug toxicity even with the regular doses. In another study, CYP2B6*6 has been demonstrated to be responsible for the differences in plasma drug levels and dose requirements. Additionally, propofol pharmacodynamics are affected by variations in the genes coding for GABA_A target receptors (GABRE). Furthermore, another study suggests that the extensive variability of patient susceptibility could be attributed to a much greater range of genes including the dominant variations in GABAA1 rs2279020, GABAA2 rs11503014, and CHRM2 rs1824024.

Cytochrome P450 family (CYP450), ATP-binding cassette (ABC1), serine/threonine-protein kinase 3 (TAOK3), family with sequence similarity 53 member B (FAM53B), and the cannabinoid receptor (CNR1) are postulated to be involved in propofol pharmacokinetics; opioid receptors (OPRM1 and OPRD1), β-adrenoceptor (ADRB1), Catechol-O-methyltransferase (COMT), and ligand-gated ion channel (P2RX7) are postulated to be directly or indirectly involved in the pharmacodynamic response to propofol; nitric oxide synthase (NOS3), GABA type A (GABA_A) receptor, NMDA receptors (GR1N3A and GR1N2B), Galanin (GAL), fatty acid amide hydrolase (FAAH), 5-hydroxytryptamine receptor (5HT2A), cholinergic receptors (CHRM2 and CHRNA5), dopamine transporters (DAT and DRD2), casein kinase (CSNK1E), calcium channels, potassium channels (KCNS1 and GIRK), and sodium channels (SCN9A) are also likely involved in the action of propofol. However, the gene variants so far studied have not shown any significant clinical differences.

**Neuromuscular blockade**

For neuromuscular blockade, ERAS Society guidelines have recommended the use of short-acting rather than long-acting neuromuscular blockers. Monitoring the depth of the blockade with a Train of Four (TOF) nerve stimulator is essential to ensure adequate deep block during surgery and satisfactory reversal of the block at the time of emergence and recovery. A TOF ratio of 0.9 has been shown to be associated with sufficient neuromuscular recovery and increased patient satisfaction at recovery. Additionally, the new reversal agent for neuromuscular blockade, Sugammadex®, may provide faster reversal than traditional anticholinesterases, with comparable side effects, allowing for quick and safe recovery.

From a pharmacogenomics standpoint, genetic polymorphism of the butyrylcholinesterase (BCHE) enzyme is one of the most common examples of discrepancies in patients’ drug response in the perioperative settings. BCHE is responsible for metabolizing succinylcholine in the plasma and liver. Patients having mutant alleles (BCHE*FS126, BCHE*13E4-14C, and BCHE*328D) have been shown to experience longer duration of muscle relaxation than patients with wild-type alleles. Specifically, patients with homozygous mutant alleles are susceptible to more prolonged relaxation than patients with heterozygous alleles. Thus, variability of genetic expression of this enzyme affects patients’ outcomes and could result in longer hospital stay with higher incidence of postoperative morbidity and mortality.

Mei et al demonstrated that the SLCO1B1 and ABCB1 gene variants might affect rocuronium action, and the ABCB1 rs1128503 C>T genotype was the main factor involved in rocuronium effectiveness. Similarly, malignant hyperthermia is another example of the genetic expression variability which may result in significant differences in patient response to administered drugs in the perioperative settings. Episodes of malignant hyperthermia may be brought about after the administration of succinylcholine in some patients. These examples show the importance of pharmacogenomic testing and how significant it is to evaluate patients’ genes and test their responses to drugs before administration.
Therefore, genetics-guided pharmacotherapy and pharmacogenomics testing should play a central role in ERAS practices to help reduce drug toxicities, optimize patient’s drug responses, and thus experience better outcomes and earlier discharge.

**Antiemetics**

Postoperative nausea and vomiting (PONV) is a major challenge that should be overcome to ensure an enhanced recovery and shorter length of stay. Prophylaxis against PONV helps with patient satisfaction and early discharge. Preoperative antiemetic drugs have been shown to be effective with PONV control. Use of a combination of medications appears more effective than single drug use. Patients with medium risk should receive 1–2 prophylactic antiemetic drugs, while high-risk patients should receive 2–3 drugs. Non-pharmacologic interventions including: reduction of preoperative fasting, use of carbohydrate-loaded drinks, avoidance of opiates, use of regional anesthetic techniques whenever possible, and propofol-based total intravenous anesthesia also have a valuable contribution to PONV control.

5-hydroxytryptamine type 3 (5-HT3) is the most common target receptor for drugs used for PONV. It has been shown that antagonism of these receptors results in a meaningful reduction of PONV. Polymorphism of the 5-HT3B receptor gene has been studied and revealed that deletion variants may be a pharmacogenetic predictor for patient responsiveness to ondansetron use for PONV. Other receptors that may play a role in PONV are dopamine type 2 receptors and mu-opioid receptors. The Dopamine D2 receptor Taq IA polymorphism has been associated with early incidence of PONV. Additionally, mu-opioids receptors’ polymorphisms have been studied and revealed that heterozygous polymorphisms might be related to less opioid consumption with reduced side effects, including opioid-induced PONV, when compared to homozygous polymorphisms. Sugino et al demonstrated that specific sets of SNP genotypes in the OPRM1 gene might contribute to individual responses to opioid medication and severity of PONV, preoperative genotyping being advised for patients at risk.

**Postoperative ileus management**

Postoperative ileus (POI) can be defined as transient episode of gut motility impairment after surgery leading to abdominal distension, vomiting, food intolerance, and late elimination. Besides increased hospitalization costs, this could result in longer hospital stay and increasing susceptibility to its associated morbidities as hospital-acquired infections or venous thromboembolism. Several approaches have been studied to reduce POI including enhanced recovery protocols. Other recent targeted interventions, such as intravenous lidocaine, chewing gum, and peripheral mu antagonists, have been investigated. However, the clinical evidence for many of these remains controversial.

The pharmacological therapeutic strategies for POI included prokinetics and peripheral mu antagonists. Most of the prokinetics used for POI are metabolized by hepatic CYP 450 enzymes system; particularly CYP2D6 for metoclopramide and CYP3A4 for cisapride. These prokinetics are known for their critical cardiovascular and neurological side effects. Genetic variations in the metabolic enzymes of these drugs predispose patients to discrepancies in drug efficacy and toxicity. For instance, genetic polymorphisms in the CYP2D6 gene have been shown associated with variability in metoclopramide side effects. Patients with certain polymorphisms, such as rs1080985 and rs16947, have been found to experience fewer side effects than usual while other patients with a different polymorphism such as rs3892097 have shown higher incidence of side effects than expected. Not only the CYP2D6 genetic variations have shown an association with metoclopramide metabolism and side effects, but KCNH2 and HTR4 genetic polymorphisms also have shown variable tendencies for adverse effects. Additionally, the clinical efficacy of metoclopramide has been associated with polymorphisms in ADRA1D genes. Understanding these genetic variations would help with better managing the perioperative administration of metoclopramide to provide the optimum therapeutic effects, while minimizing side effects and length of hospitalization.

**Volatile anesthetics**

There is limited evidence regarding genetic variations and response to volatile anesthetics (VAs), and few population-based studies have been conducted. It is important to remember that VAs are mostly eliminated through the lungs rather than kidneys and liver. In fact, less than 5% of currently used VAs are metabolized (sevoflurane, 2%, isoflurane <1%, desflurane 0.1%). There is also partial elimination by biotransformation mediated by the cytochrome enzyme CYP2E1. There are known genetic variations of CYP2E1, although there are no studies addressing clinical importance of this variation. Genetic variation has
been implicated in emergence agitation in response to VAs in children. One study of children undergoing tonsillectomy and adenoidectomy with sevoflurane anesthesia showed that the AA group in the GABRgamma2-nucleotide position 3145 in intron A/G had a lower incidence of emergence agitation when compared with the non-AA group.\(^94,95\) In addition, there are studies suggesting that red heads may have higher VA requirements. One study of female red heads receiving desflurane showed that VA requirement was significantly higher than in dark-haired women, due to a mutation on the melanocortin-1 receptor gene.\(^96\)

### Counter arguments
Pharmacogenomics opened a relatively new and exciting chapter of modern science. However, the FDA warned against the use of pharmacogenetic testing to predict patient-variable responses as the practice has not yet been approved or reviewed by the administration.\(^97\) This claim is based on insufficient evidence of the proven effectiveness and reliability of pharmacogenomic testing through clinical trials.\(^97\) While the FDA is not yet advocating or supporting the use of this kind of testing, as more research and clinical trials are completed, definitive answers to questions that have arisen about the reliability of pharmacogenomics will be acquired. Also, the turnaround time (7–10 days up to 4–6 weeks) is an important factor when the test is decided for the patient who needs fast results to prescribe a medication versus the non-urgent preemptive decision.\(^98\)

### Future direction
Improvement of knowledge on ERAS practices is critical to advance the clinical practice and minimize the gap between knowing and doing.\(^99\) With the current evidences and experiences gained from ERAS practices, it is reasonable to consider ERAS for all surgical procedures and tailoring its practices to suit procedure and patient-specific needs. Now with the evolution of pharmacogenomics, genetics-guided pharmacotherapy, and its impact on clinical outcomes should be thoroughly studied for better understanding and managing drug administration in the settings of ERAS.

### Conclusion
ERAS practices are composed of several elements and many of these involve drug administration. Personalized drug administration in the perioperative settings could play a central role in ERAS practices as it helps reduce drug toxicities and optimize patient’s drug responses.\(^100\) If a certain drug is given, do we know the correct dose? Would genotyping and phenotyping the patient be enough in order to decide on therapy? For new associated drugs, can any drug interaction be preemptively avoided by pharmacogenomic testing? These are the questions awaiting more definitive data from future research initiatives. Therefore, genetics-guided pharmacotherapy and pharmacogenomics testing have great potential to improve patient outcomes, earlier discharge, and lower health care costs matching ERAS objectives.

### Acknowledgments
We acknowledge the contribution (editing the final version of the manuscript) of pre-med students Andrew Costa (The Ohio State University, Columbus, OH, USA) and Garegin Soghomonyan (Claremont McKenna College, Claremont, CA, USA).

### Disclosure
Richard D Urman received research funding from CQuentia Inc. Sergio D Bergese reports personal fees from Baxter, outside the submitted work. The authors report no other conflicts of interest in this work.

### References


